Effectiveness of glycosaminoglycan in patients with glomerulonephritis: A prospective longitudinal cohort study

DOI: https://doi.org/10.31450/ukrjnd.3(75).2022.03
Keywords: chronic kidney disease, glomerulonephritis, treatment, glycosaminoglycans, sulodexide.

Abstract

Abstract. Our study aimed to evaluate the effectiveness of Sulodexide in the treatment of patients with glomerulonephritis(GN).

Methods. We conducted a prospective longitudinal cohort study involving 105 patients with CKD, who were hospitalized at the Ivano-Frankivsk Regional Clinical Hospital (Ukraine) from 2021-2022. Only patients with proteinuria of 0.3 g – 3.5 g/day and chronic kidney disease (CKD) stages 1-3 and the diagnosis of GN were included in the study. The clinical diagnosis was determined based on standard examination methods according to the Classification of Kidney Diseases and protocols of management of CKD patients

All patients were randomly assigned into 2 groups. Group 1 received basic therapy, and Group 2 received Sulodexide in oral capsules containing 250 lipasemic units (LSU) twice daily in addition to basic therapy. The duration of treatment was 6 months.

 Results. Our study showed that the additional use of sulodexide for 6 months significantly reduced the level of proteinuria in patients with GN, so in the second group, it was possible to achieve a significantly lower level of proteinuria 567 (356; 745) mg/day, compared to the first group 956 (765; 1233 ) mg/day (р˂0.05).

 As the glomerular filtration rate remained stable or even increased, proteinuria reduction cannot be explained by alteration of filtration capacity. We also noted a significant decrease in the level of D-dimers in the group of patients who additionally received Sulodexide for 6 months, which may indicate the prevention of thromboembolic and cardiovascular events in this population of patients. However, this hypothesis needs further research.

Conclusions. The additional use of Sulodexide in patients with GN statistically significantly reduced proteinuria levels preventing CKD progression rate.

Downloads

Download data is not yet available.

References

Kolesnyk M. Innovative directions of CKD prevention and treatment. Ukr J Nephr Dial. 2019;1(61):3-12. doi: 10.31450/ukrjnd.1(61).2019.01  

Dudar ІО,   Savchuk VM,    Loboda ОМ,    Krasiuk EK.   Hyperprolactinemia in  patients with  chronic kidney disease. Ukr   J  Nephr Dial.    2021;1(69):61-66. doi:    10.31450/ukrjnd.1(69).2021.09

Stepanova  N,  Snisar  L,  Lebid  L,  Driianska  V.  Crosstalk  between  nephrotic  proteinuria,  plasma  oxalic  acid  and  inflammation  in  glomerulonephritis patients: an exploratory study. Ukr J Nephr Dial. 2021;3(71):19-27. doi: 10.31450/ukrjnd.3(71).2021.03.

Gaddi AV, Cicero AF, Gambaro G. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis. 2010;3:99-105.  doi: 10.2147/IJNRD.S5943. 

Masola V, Zaza G, Gambaro G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant. 2014; 29: i74–i79.  doi : 10.1093/ndt/gft389. 

Li R, Xing J, Mu X, Wang H, Zhang L, Zhao Y, Zhang Y. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015;9:6275-83. doi:10.2147/DDDT.S87973.

Bang K, Chin HJ, Chae DW, Joo KW, Kim YS, Kim S, Ju KD, Kim H, Ahn C, Oh KH. Anti-proteinuric effect of sulodexide in Immunoglobulin A nephropathy. Yonsei Med J. 2011;52(4):588-94. doi:10.3349/ymj.2011.52.4.588

Bignamini AA, Chebil A, Gambaro G, Matuška J. Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. Adv Ther. 2021;38(3):1483-1513. doi: 10.1007/s12325-021-01620-1.

De Felice F, Megiorni F, Pietrantoni I, Tini P, Lessiani G, Mastroiacovo D, Mattana P, Antinozzi C, Di Luigi L, Delle Monache S, Angelucci A, Festuccia C, Fanzani A, Maggio R, Tombolini V, Gravina GL, Marampon F. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci. 2019;23(6):2669-2680. doi: 10.26355/eurrev_201903_17415.

Yongwatana K, Supasyndh O, Satirapoj BJ. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria. Diabetes Res. 2020;2020:2984680. doi: 10.1155/2020/2984680.

 Masola V, Onisto M, Zaza G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2- induced renal epithelial-mesenchymal transition. J Transl Med. 2012; 10: 213. doi: 10.1186/1479-5876-10-213.

Zilisteanu DS, Atasie T, Voiculescu M. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies. Rom J Intern Med. 2015;53(2):161-9.  doi: 10.1515/rjim-2015-0022.   

 Siddiqui F, Hoppensteadt D, Bontekoe E, Farooqui A, Jeske W, Fareed J. Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components. Clin Appl Thromb Hemost. 2020;26:1076029620954913. doi: 10.1177/1076029620954913.

Mykhaloiko IS, Dudar IO, Mykhaloiko IJ, Mykhaloiko OJ. D-dimer as a potential predictor of thromboembolic and cardiovascular complications in patients with chronic kidney disease. Ukr. Biochem. J. 2020; Vol. 92, N 3:71-76. doi: 10.15407/ubj92.03.071.


Abstract views: 560
PDF Downloads: 13173
Published
2022-08-06
How to Cite
Mykhaloiko, I., Yatsyshyn, R. ., & Dudar, I. (2022). Effectiveness of glycosaminoglycan in patients with glomerulonephritis: A prospective longitudinal cohort study. Ukrainian Journal of Nephrology and Dialysis, (3(75), 22-27. https://doi.org/10.31450/ukrjnd.3(75).2022.03
Issue
No 3(75) (2022): Ukrainian Journal of Nephrology and Dialysis
Section
Original Papers
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.